NO20034741D0 - Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser - Google Patents

Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser

Info

Publication number
NO20034741D0
NO20034741D0 NO20034741A NO20034741A NO20034741D0 NO 20034741 D0 NO20034741 D0 NO 20034741D0 NO 20034741 A NO20034741 A NO 20034741A NO 20034741 A NO20034741 A NO 20034741A NO 20034741 D0 NO20034741 D0 NO 20034741D0
Authority
NO
Norway
Prior art keywords
deoxypeganine
poisoning
treatment
nervous system
central nervous
Prior art date
Application number
NO20034741A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034741L (no
Inventor
Klaus Opitz
Joachim Moormann
Thomas Hille
Frank Becher
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20034741(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of NO20034741D0 publication Critical patent/NO20034741D0/no
Publication of NO20034741L publication Critical patent/NO20034741L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20034741A 2001-04-24 2003-10-23 Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser NO20034741L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119863A DE10119863A1 (de) 2001-04-24 2001-04-24 Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
PCT/EP2002/004278 WO2002087553A2 (de) 2001-04-24 2002-04-18 Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (2)

Publication Number Publication Date
NO20034741D0 true NO20034741D0 (no) 2003-10-23
NO20034741L NO20034741L (no) 2003-10-23

Family

ID=7682410

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034741A NO20034741L (no) 2001-04-24 2003-10-23 Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser

Country Status (27)

Country Link
US (1) US20040132751A1 (pl)
EP (1) EP1383503B1 (pl)
JP (1) JP2004526791A (pl)
KR (1) KR20030094365A (pl)
CN (1) CN1638774A (pl)
AR (1) AR033469A1 (pl)
AT (1) ATE411024T1 (pl)
AU (1) AU2002325209B2 (pl)
BR (1) BR0209125A (pl)
CA (1) CA2445132C (pl)
CZ (1) CZ20032788A3 (pl)
DE (2) DE10119863A1 (pl)
DK (1) DK1383503T3 (pl)
EA (1) EA200301134A1 (pl)
ES (1) ES2316595T3 (pl)
HU (1) HUP0303921A3 (pl)
IL (1) IL158383A0 (pl)
MX (1) MXPA03009766A (pl)
MY (1) MY135676A (pl)
NO (1) NO20034741L (pl)
NZ (1) NZ529005A (pl)
PL (1) PL366845A1 (pl)
PT (1) PT1383503E (pl)
SI (1) SI1383503T1 (pl)
SK (1) SK287214B6 (pl)
WO (1) WO2002087553A2 (pl)
ZA (1) ZA200308042B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
ES2360547B1 (es) * 2009-11-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de obtención de los alcaloides activos de la planta medicinal peganum harmala y su uso.
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (pl) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19924951B4 (de) * 1999-05-31 2004-02-05 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
EP1231877A4 (en) * 1999-11-04 2009-03-18 Xel Herbaceuticals TRANSDERMALE ADMINISTRATION OF HUPERZIN

Also Published As

Publication number Publication date
SI1383503T1 (sl) 2009-04-30
DE50212901D1 (de) 2008-11-27
HUP0303921A3 (en) 2011-03-28
BR0209125A (pt) 2004-07-27
CA2445132C (en) 2009-01-13
SK13162003A3 (sk) 2004-02-03
ZA200308042B (en) 2004-02-04
ES2316595T3 (es) 2009-04-16
MY135676A (en) 2008-06-30
PL366845A1 (pl) 2005-02-07
EP1383503B1 (de) 2008-10-15
DK1383503T3 (da) 2009-02-16
AU2002325209B2 (en) 2007-08-16
CZ20032788A3 (en) 2004-05-12
NZ529005A (en) 2007-11-30
CA2445132A1 (en) 2002-11-07
KR20030094365A (ko) 2003-12-11
AR033469A1 (es) 2003-12-17
SK287214B6 (sk) 2010-03-08
WO2002087553A2 (de) 2002-11-07
HK1062402A1 (zh) 2004-11-05
ATE411024T1 (de) 2008-10-15
JP2004526791A (ja) 2004-09-02
US20040132751A1 (en) 2004-07-08
NO20034741L (no) 2003-10-23
HUP0303921A2 (hu) 2004-03-01
CN1638774A (zh) 2005-07-13
MXPA03009766A (es) 2005-04-19
EA200301134A1 (ru) 2004-04-29
PT1383503E (pt) 2009-01-07
DE10119863A1 (de) 2002-11-07
IL158383A0 (en) 2004-05-12
WO2002087553A3 (de) 2003-02-27
EP1383503A2 (de) 2004-01-28

Similar Documents

Publication Publication Date Title
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
DK2052714T3 (da) Topisk gel-fremføringssystem til behandling af hudlidelser
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DK1339406T3 (da) Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
IS7941A (is) Bensasepínafleiður til að meðhöndla taugasjúkdóma
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20022585L (no) Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
EP1625207A4 (en) COMPOUNDS FOR THE TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISEASES
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
IS6137A (is) Meðhöndlun á hugsýkistruflunum
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
ATE292107T1 (de) Verwendung von carbonylaminoderivaten gegen zentralnervensystem-störungen
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
IL152688A0 (en) Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
NO20023803D0 (no) Anvendelse av mirtazapin for behandling av sövnforstyrrelser
NO20032156L (no) Behandling av angstforstyrrelser
NO20034740L (no) Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser
DE69923464D1 (de) Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems
NO20014953D0 (no) Anvendelse av osanetant for fremstilling av medikamenter anvendt for å behandle sinnsstemningslidelser
NO20024331D0 (no) Behandling av lidelser relatert til det serotonerge system